EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category  |
Confidence Level |
|---|
   1.8.98.2 | Carcinogenesis |
23393226 |
Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis. |
causal interaction
ongoing research
unassigned |
1
3
0 |
| 1.8.98.2 | Carcinogenesis |
24503444 |
Tumor promoter-induced sulfiredoxin is required for mouse skin tumorigenesis. |
causal interaction
unassigned |
2
0 |
| 1.8.98.2 | Carcinogenesis |
32746503 |
SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
4
4
4 |
| 1.8.98.2 | Lung Neoplasms |
22016591 |
Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. |
causal interaction
unassigned |
2
0 |
| 1.8.98.2 | Lung Neoplasms |
31000628 |
The redox regulator sulfiredoxin forms a complex with thioredoxin domain-containing 5 protein in response to ER stress in lung cancer cells. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
4
1
1 |
| 1.8.98.2 | Neoplasms |
21943684 |
Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
2
2
3 |
| 1.8.98.2 | Neoplasms |
29441509 |
NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas. |
causal interaction
unassigned |
1
0 |
| 1.8.98.2 | Neoplasms |
32411320 |
Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
2
4 |
| 1.8.98.2 | Carcinoma, Hepatocellular |
32746503 |
SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
4
4
4 |
| 1.8.98.2 | Adenocarcinoma |
32411320 |
Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
2
4 |
